Stellar-002: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors

Condition: Liver Cancer, Renal Cell Carcinoma


Go To Trial Homepage